Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

14th Euro-Global Gastroenterology Conference

Zurich, Switzerland

Balwant Singh Gill

Dr. MGR Medical University, India

Title: Pathophysiology and management of "Esophageal Varices" in current practice

Biography

Biography: Balwant Singh Gill

Abstract

Esophageal varices: Esophageal varices are dilated submucosal distal esophageal veins connecting the portal and systemic circulations. Th is happens due to portal hypertension (most commonly a result of cirrhosis), resistance to portal blood fl ow and increased portal venous blood infl ow. Th e most common fatal complication of cirrhosis is variceal rupture; the severity of liver disease correlates with the presence of varices and risk of bleeding.
Bleeding esophageal varices: No single treatment for bleeding Esophageal varices is appropriate for all patients and situations. An algorithm for management of the patient with acute bleeding is presented in this article. The options for long-term, defi nitive therapy and the criteria for selection of each are discussed.Pathophysiology and management of esophageal varices: Esophageal varices are one of the most common and severe complications of chronic liver diseases. New aspects in epidemiology, pathogenesis and treatment of varices are reviewed. Sclerotherapy is the fi rst-line treatment for acute hemorrhage. Prevention of first or recurrent bleeding is still unsatisfactory. β-Blockers are slightly superior to sclerotherapy with regard to prophylaxis of fi rst bleeding.β-Blockers or sclerotherapy may be used for prophylaxis of recurrent bleeding. However, prophylactic treatment regimens do not have a major impact on survival. Combination treatment, new drugs or new devices may help to improve the effi cacy of prophylactic measures. Endoscopic therapy for esophageal varices: Among therapeutic endoscopic options for Esophageal varices (EV), Endoscopic variceal ligation (EVL) has proven more eff ectiveness and safety compared with endoscopic sclerotherapynd is currently considered as the first choice. In acute EV bleeding, vasoactive therapy (either with terlipressin or somatostatin) prior to endoscopy improves outcomes; moreover, antibiotic prophylaxis has to be generally adopted. Variceal glue injection (cyanoacrylates) seems to be effective in the treatment of esophageal as well as in gastric varices. Prevention of rebleeding can be provided both by EVL alone or combined with non-selective β-blockers. Moreover, EVL can be adopted for primary prophylaxis, with no differences in mortality compared with drugs, in subjects with large varices and unfi t for a β-blocker regimen. A meta‐analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding: Despite publication of several randomized trials of prophylactic ariceal ligation, the effect on bleeding‐related outcomes is unclear. We performed a meta‐analysis of the trials, as identifi ed by electronic database searching and cross‐referencing. Both investigators independently applied inclusion and exclusion criteria and abstracted data from each trial. Standard meta‐analytic techniques were used to compute relative risks and the number needed to treat (NNT) for first variceal bleed, bleed‐related mortality and all‐cause mortality. Among 601 patients in 5 homogeneous trials comparing prophylactic ligation with untreated controls, relative risks of fi rst variceal bleed, bleed‐related mortality and all‐cause mortality were 0.36 (0.26‐0.50), 0.20 (0.11‐0.39) and 0.55 (0.43‐0.71), with respective NNTs of 4.1, 6.7 and 5.3. Among 283 subjects from 4 trials comparing ligation with β‐blocker therapy, the relative risk of fi rst variceal bleed was 0.48 (0.24‐0.96), with NNT of  13; However, there was no eff ect on either bleed‐related mortality (relative risk [RR], 0.61).